Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
PAR PHARMACEUTICAL COMPANIES, INC. (PRX)
|
Add to portfolio |
|
|
|
| Price: |
$28.80
| | Metrics |
| OS: |
|
| |
-17
|
% ROE
|
| Market cap: |
$2.9
|
k
| |
32
|
% ROIC
|
|
Net debt:
|
$2.18
|
B
| |
3.9
|
x Debt/EBITDA
|
|
EV:
|
$2.18
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$563
|
M
| |
3.9
|
x EV/EBITDA
|
|
EBIT
|
$344
|
M
| |
6.3
|
x EV/EBIT
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-14 | Dec-31-13 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 1,308.6 | 1,097.5 | 926.1 | 1,008.9 | 1,193.2 | 578.1 | 769.7 | 725.2 |
| Revenue growth | 19.2% | | -8.2% | -15.4% | 106.4% | -24.9% | 6.1% | 67.8% |
| Cost of goods sold | 1,043.0 | 987.0 | 565.7 | 663.2 | 892.8 | 401.5 | 501.1 | 506.9 |
| Gross profit | 265.6 | 110.5 | 360.4 | 345.7 | 300.4 | 176.6 | 268.5 | 218.3 |
| Gross margin | 20.3% | 10.1% | 38.9% | 34.3% | 25.2% | 30.5% | 34.9% | 30.1% |
| Selling, general and administrative | 181.1 | 155.2 | 173.4 | 192.5 | 165.1 | 137.9 | 138.2 | 148.2 |
| Research and development | 119.1 | 100.8 | 46.5 | 50.4 | 39.2 | 59.7 | 77.7 | 61.8 |
| EBITA | 170.4 | 60.3 | 154.8 | 152.7 | 154.8 | -61.5 | 73.2 | 9.4 |
| EBITA margin | 13.0% | 5.5% | 16.7% | 15.1% | 13.0% | -10.6% | 9.5% | 1.3% |
| Amortization of intangibles | | | 14.8 | 16.0 | 23.1 | | | |
| EBIT | 170.4 | 60.3 | 140.0 | 136.7 | 131.8 | -61.5 | 73.2 | 9.4 |
| EBIT margin | 13.0% | 5.5% | 15.1% | 13.5% | 11.0% | -10.6% | 9.5% | 1.3% |
| Pre-tax income | -178.5 | -167.1 | -52.3 | 134.7 | 126.5 | -85.8 | 71.5 | 8.8 |
| Income taxes | -73.0 | -61.2 | -6.0 | 42.0 | 48.9 | -86.3 | 24.7 | 2.1 |
| Tax rate | 40.9% | 36.6% | 11.5% | 31.2% | 38.6% | 100.6% | 34.5% | 23.4% |
| Earnings from continuing ops | -105.5 | -105.9 | -46.3 | 92.8 | 77.6 | 0.5 | 46.8 | 6.7 |
| Earnings from discontinued ops | | | | | | 0.5 | | |
| Net income | -105.5 | -105.9 | -26.1 | 92.7 | 76.9 | 0.5 | 45.6 | 5.8 |
| Net margin | -8.1% | -9.6% | -2.8% | 9.2% | 6.4% | 0.1% | 5.9% | 0.8% |
| |
| Diluted EPS | | | ($1.29) | $2.60 | $2.27 | $0.02 | $1.35 | $0.19 |
| Shares outstanding (diluted) | | | 36.0 | 35.6 | 34.2 | 33.3 | 34.7 | 34.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|